ACADIA Pharmaceuticals Inc.

ACAD

Held by 12 specialist biotech funds

High Convergence

12 funds opened new positions. Next phase3 readout (Carbetocin): Oct 2025. Short interest: 7.6% of float.

BiotechnologyCEO: Catherine E. Owen AdamsIPO: 2004Website ↗

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Catalysts

Phase 2Q4 2005ACP-103Hallucinations, Psychoses, Parkinson's DiseaseNCT00087542

Primary: ACP-103 is an effective treatment for Parkinson's Disease with psychosisEnrollment:Target 60Sites: 13RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2007ACP-103SchizophreniaNCT00361166

Primary: Total score on the Positive and Negative Symptom Scale (PANSS).Enrollment:Target 400Sites: 17RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2008ACP-104SchizophreniaNCT00490516

Primary: PANSS (6 weeks)Enrollment:247/247Sites: 21RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2009Pimavanserin tartrate (ACP-103)Parkinson's Disease PsychosisNCT00477672

Primary: Antipsychotic Efficacy (Each study visit (i.e. Days 1, 8, 15, 29 and 42))Enrollment:298/298Sites: 78RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2009Pimavanserin tartrate (ACP-103)Parkinson's Disease PsychosisNCT00658567

Primary: Antipsychotic Efficacy (Each study visit (i.e. Days 1, 8, 15, 29 and 42))Enrollment:123/123Sites: 50RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2012pimavanserin tartrateParkinson's Disease PsychosisNCT01174004

Primary: Antipsychotic Efficacy (Each study visit (i.e. Days 1, 15, 29 and 43))Enrollment:199/199Sites: 63RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2013pimavanserin tartrate (ACP-103)Parkinson's Disease PsychosisNCT01518309

Primary: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) (From first to last study drug dose plus 30 days)Enrollment:39/39Sites: 1NA, TREATMENT

Phase 2PositiveQ3 2016Pimavanserin tartrateAlzheimer's Disease PsychosisNCT02035553

Primary: Antipsychotic Efficacy (Day 43)Enrollment:181/181Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ1 2018Pimavanserin 34 mgAgitation and Aggression in Alzheimer's DiseaseNCT02992132

Primary: Cohen-Mansfield Agitation Inventory (CMAI) (Baseline to 12 weeks)Enrollment:111/111Sites: 56RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2018Pimavanserin tartrate (ACP-103)Parkinson's Disease PsychosisNCT00550238

Primary: Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) (From first to last study drug dose plus 30 days)Enrollment:459/459Sites: 135NA, TREATMENT

Phase 2NegativeQ3 2018PimavanserinAdjunctive Treatment of Major Depressive DisorderNCT03018340

Primary: Change From Baseline to Week 5 in the HAMD-17 Total Score (Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively)Enrollment:207/207Sites: 36RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ2 2019PimavanserinSchizophreniaNCT02970292

Primary: Change From Baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (From baseline to Week 6)Enrollment:396/396Sites: 105RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2019PimavanserinTreatment of Depression in Adults With Parkinson's Disease (PD)NCT03482882

Phase 3PositiveQ3 2019Dementia-related PsychosisNCT03325556

Phase 2NegativeQ4 2019PimavanserinSchizophreniaNCT02970305

Phase 3Q2 2020PimavanserinAdjunctive Treatment of Major Depressive DisorderNCT03968159

Primary: Change From Baseline to Week 5 in Hamilton Depression Scale (17 Items) (HAMD-17) Total Score (Baseline, Week 5)Enrollment:298/298Sites: 85RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2020PimavanserinParkinson's DiseaseNCT04164758

Primary: Treatment-emergent Adverse Events (TEAEs) (4-week treatment duration, plus 30 days treatment-free safety follow-up)Enrollment:11/11Sites: 16RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2021PimavanserinAdjunctive Treatment of Major Depressive DisorderNCT04000009

Phase 3ApprovedQ4 2021TrofinetideRett SyndromeNCT04181723

Primary: Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12 (Baseline and Week 12)Enrollment:187/187Sites: 21RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2022ACP-044 Dose AAcute Postoperative Pain, BunionectomyNCT04855240

Phase 3Q2 2022PimavanserinNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03575052

Phase 3ApprovedQ3 2022TrofinetideRett SyndromeNCT04279314

Phase 3ApprovedQ2 2023TrofinetideRett SyndromeNCT04988867

Phase 3NegativeQ2 2023trofinetideRett SyndromeNCT04776746

Phase 3Q1 2024PimavanserinSchizophreniaNCT04531982

Phase 3NegativeQ2 2024PimavanserinSchizophreniaNCT03121586

Phase 3Q3 2024PimavanserinIrritability Associated With Autism Spectrum DisorderNCT05523895

Phase 3NegativeQ1 2025PimavanserinIrritability Associated With Autism Spectrum DisorderNCT05555615

Phase 3Q4 2025CarbetocinHyperphagia in Prader-Willi SyndromeNCT06173531

Primary: Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score (Baseline to Week 12)Enrollment:Target 170Sites: 30RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Dec 31, 2026Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]Autism Spectrum DisorderNCT05999240

Primary: Evaluate the impact of a single dose of pimavanserin 34 mg versus placebo (Post Intervention, 30 days after study completion)Enrollment:Target 30Sites: 2RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2027Pimavanserin 34 mgIntermittent Explosive DisorderNCT05895513

Primary: Aggressive Responding on the Taylor Aggression Paradigm (TAP) (The TAP will be done about five (5) hours after administration of pimavanserin and after placebo.)Enrollment:Target 35Sites: 1RANDOMIZED, QUADRUPLE, BASIC_SCIENCE

Phase 2Q3 2027ACP-211Major Depressive Disorder (MDD), Depressive Disorder, Treatment-ResistantNCT07284667

Phase 3Q1 2028ACP-204Alzheimer's Disease PsychosisNCT06159673

Phase 2Q1 2028ACP-204Lewy Body Dementia PsychosisNCT07029581

Phase 3Q1 2029ACP-204Lewy Body Dementia PsychosisNCT07095465

Phase 3Q2 2029ACP-204Alzheimer's Disease PsychosisNCT06194799

Primary: Treatment-emergent adverse events (52 Weeks)Enrollment:Target 752Sites: 76NA, TREATMENT

Recent News & Research

PubMed

Retraction statement: Carbetocin versus syntometrine for prevention of postpartum hemorrhage after cesarean section.

# Summary for ACADIA Investors This article is a **retraction notice unrelated to ACADIA's pipeline** — it concerns obstetric medications (carbetocin and syntometrine) for preventing postpartum hemorrhage, with no connection to ACADIA's focus areas (psychiatry, neurology, and rare diseases). **Why this doesn't matter for ACADIA investors:** This retracted study has no bearing on ACADIA's clinical programs, competitive landscape, or commercial prospects. Investors should disregard this reference unless tracking it for academic integrity concerns in the broader medical literature.

Dec 1, 2026

PubMed

Retraction statement: carbetocin versus oxytocin for prevention of postpartum hemorrhage in obese nulliparous women undergoing emergency cesarean delivery.

I cannot provide the summary you've requested because this article is a retraction statement from December 2026—a future date. The article does not appear to relate to ACADIA Pharmaceuticals' core pipeline (pimavanserin for Parkinson's psychosis, ulotaront for schizophrenia, etc.), as it concerns obstetric medications (carbetocin/oxytocin). For investment analysis, I'd recommend: (1) confirming the actual publication date and journal, (2) verifying if ACADIA has any obstetric programs I'm unaware of, or (3) providing a different article directly relevant to ACAD's clinical programs or commercial performance.

Dec 1, 2026

PubMed

Rett syndrome and real-world treatment patterns of trofinetide in the United States.

# Investment Summary: ACADIA Pharmaceuticals - Trofinetide Real-World Data **Key Finding:** This real-world evidence study documents actual trofinetide utilization patterns in US Rett syndrome patients, providing data on treatment adoption rates, dosing compliance, and patient persistence post-launch that directly inform revenue forecasting and market penetration estimates. **Why It Matters for Investors:** Real-world treatment pattern data is critical for validating commercial assumptions around trofinetide's (Fintepla) peak sales potential and identifying gaps between clinical trial efficacy and actual clinical adoption. If the study reveals suboptimal dosing, early discontinuation, or limited eligible patient identification, it would suggest lower revenue realization; conversely, strong persistence data would support management's commercial guidance and justify the drug's contribution to ACAD's revenue base in this rare disease indication.

Dec 1, 2026

PubMed

The Effect of Carbetocin on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled QT/QTc Study in Healthy Adults.

# ACAD Investment Summary This QT/QTc safety study evaluates carbetocin's cardiac electrophysiology profile in healthy volunteers, establishing baseline safety data that would support regulatory submissions and reduce development risk for any cardiac-related adverse event concerns. The results are relevant if carbetocin is in ACAD's pipeline; a clean safety profile de-risks regulatory approval pathways and expansion into broader patient populations, while any QT prolongation findings could require label restrictions or additional monitoring protocols that impact commercial potential. **Investor Relevance:** Confirm whether carbetocin is actively developed by ACAD and assess if this study directly supports an ongoing regulatory program—positive outcomes strengthen approval odds and reduce clinical trial risk.

Oct 1, 2026

PubMed

Carbetocin and oxytocin use in emergency cesarean delivery: a prospective observational study of 24-hour bleeding outcomes.

# Research Summary for ACAD Investment Tracking I don't have access to the full text of this specific 2026 article, so I cannot provide an accurate summary of its findings and clinical conclusions. However, I can note that **this study would NOT appear directly relevant to ACAD's core pipeline**, as ACADIA's primary focus is CNS disorders (schizophrenia, Parkinson's disease psychosis, depression) rather than obstetric medications. Carbetocin and oxytocin are uterotonic agents used in obstetrics—outside ACAD's therapeutic areas. **To provide useful investor analysis, I would need:** - The study's primary findings on carbetocin vs. oxytocin efficacy/safety - Whether ACADIA has any undisclosed obstetrics programs - Confirmation this isn't related to a recent acquisition or pipeline expansion If you're tracking

Jul 11, 2026

ACADIA Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Cash Runway

Short Interest

Catalysts

Activist Filings

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research